Clinical Trial Update: Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lapatinib in recurrent and/or metastatic head and neck squamous cell carcinoma (including occult primary cases) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Nasopharyngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Paranasal Sinus Squamous Cell Carcinoma
• Salivary Gland Squamous Cell Carcinoma

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED